Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer
Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells that are closely related to tumor immune escape, but the mechanism by which MDSCs regulate B cells has not been elucidated. Our previous studies revealed that breast cancer-derived MDSCs could induce a group...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-05-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-021-03745-1 |
id |
doaj-fb96144fb940497ab9f2207d5c9685b4 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Min Liu Feng Wei Jian Wang Wenwen Yu Meng Shen Ting Liu Dong Zhang Yang Wang Xiubao Ren Qian Sun |
spellingShingle |
Min Liu Feng Wei Jian Wang Wenwen Yu Meng Shen Ting Liu Dong Zhang Yang Wang Xiubao Ren Qian Sun Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer Cell Death and Disease |
author_facet |
Min Liu Feng Wei Jian Wang Wenwen Yu Meng Shen Ting Liu Dong Zhang Yang Wang Xiubao Ren Qian Sun |
author_sort |
Min Liu |
title |
Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer |
title_short |
Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer |
title_full |
Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer |
title_fullStr |
Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer |
title_full_unstemmed |
Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer |
title_sort |
myeloid-derived suppressor cells regulate the immunosuppressive functions of pd-1−pd-l1+ bregs through pd-l1/pi3k/akt/nf-κb axis in breast cancer |
publisher |
Nature Publishing Group |
series |
Cell Death and Disease |
issn |
2041-4889 |
publishDate |
2021-05-01 |
description |
Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells that are closely related to tumor immune escape, but the mechanism by which MDSCs regulate B cells has not been elucidated. Our previous studies revealed that breast cancer-derived MDSCs could induce a group of PD-1−PD-L1+ Bregs with immunosuppressive functions. Here, we reported that blocking PD-1/PD-L1 interaction between MDSCs and B cells could reverse the immunosuppressive functions of PD-1−PD-L1+ Bregs. The activation of PI3K/AKT/NF-κB signaling pathway is essential for PD-1−PD-L1+ Bregs to exert immunosuppressive effects. MDSCs activated the PI3K/AKT/NF-κB pathway in B cells via the PD-1/PD-L1 axis. Furthermore, inhibition of PD-1/PD-L1 or PI3K/AKT signaling suppressed both tumor growth and the immunosuppressive functions of PD-1−PD-L1+ Bregs. Dual suppression of PD-1/PD-L1 and PI3K/AKT exerted better antitumor effect. Finally, MDSCs and PD-1−PD-L1+ Bregs were colocalized in breast cancer tissues and PD-1−PD-L1+ Bregs were positively correlated with poor prognosis. Thus, MDSC-educated PD-1−PD-L1+ Bregs and their regulatory mechanisms could contribute to the immunosuppressive tumor microenvironment. Our study proposes a novel mechanism for MDSC-mediated regulation of B cell immunity, which might shed new light on tumor immunotherapy.+ |
url |
https://doi.org/10.1038/s41419-021-03745-1 |
work_keys_str_mv |
AT minliu myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer AT fengwei myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer AT jianwang myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer AT wenwenyu myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer AT mengshen myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer AT tingliu myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer AT dongzhang myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer AT yangwang myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer AT xiubaoren myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer AT qiansun myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer |
_version_ |
1721454775641309184 |
spelling |
doaj-fb96144fb940497ab9f2207d5c9685b42021-05-09T11:04:50ZengNature Publishing GroupCell Death and Disease2041-48892021-05-0112511510.1038/s41419-021-03745-1Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancerMin Liu0Feng Wei1Jian Wang2Wenwen Yu3Meng Shen4Ting Liu5Dong Zhang6Yang Wang7Xiubao Ren8Qian Sun9Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerAbstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells that are closely related to tumor immune escape, but the mechanism by which MDSCs regulate B cells has not been elucidated. Our previous studies revealed that breast cancer-derived MDSCs could induce a group of PD-1−PD-L1+ Bregs with immunosuppressive functions. Here, we reported that blocking PD-1/PD-L1 interaction between MDSCs and B cells could reverse the immunosuppressive functions of PD-1−PD-L1+ Bregs. The activation of PI3K/AKT/NF-κB signaling pathway is essential for PD-1−PD-L1+ Bregs to exert immunosuppressive effects. MDSCs activated the PI3K/AKT/NF-κB pathway in B cells via the PD-1/PD-L1 axis. Furthermore, inhibition of PD-1/PD-L1 or PI3K/AKT signaling suppressed both tumor growth and the immunosuppressive functions of PD-1−PD-L1+ Bregs. Dual suppression of PD-1/PD-L1 and PI3K/AKT exerted better antitumor effect. Finally, MDSCs and PD-1−PD-L1+ Bregs were colocalized in breast cancer tissues and PD-1−PD-L1+ Bregs were positively correlated with poor prognosis. Thus, MDSC-educated PD-1−PD-L1+ Bregs and their regulatory mechanisms could contribute to the immunosuppressive tumor microenvironment. Our study proposes a novel mechanism for MDSC-mediated regulation of B cell immunity, which might shed new light on tumor immunotherapy.+https://doi.org/10.1038/s41419-021-03745-1 |